Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis
Background: The present study aimed to address the effect of Rituximab on the cognitive impairment in patients with secondary progressive MS (SPMS). Methods: The present interventional study used a convenience sampling method to select the study participants from SPMS patients. All these patients ha...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Babol University of Medical Sciences
2022-06-01
|
| Series: | Caspian Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://caspjim.com/article-1-2788-en.html |
| _version_ | 1811225426357387264 |
|---|---|
| author | Saeideh Salehizadeh Roghayeh Saeidi Mohammad Ali Sahraian Hossein Rezaei Aliabadi Seyedeh Nafiseh Hashemi Sharareh Sharareh Mohammad Reza Gheini Shaghayegh Shahmirzaei Mahsa Owji Abdorreza Naser Moghadasi |
| author_facet | Saeideh Salehizadeh Roghayeh Saeidi Mohammad Ali Sahraian Hossein Rezaei Aliabadi Seyedeh Nafiseh Hashemi Sharareh Sharareh Mohammad Reza Gheini Shaghayegh Shahmirzaei Mahsa Owji Abdorreza Naser Moghadasi |
| author_sort | Saeideh Salehizadeh |
| collection | DOAJ |
| description | Background: The present study aimed to address the effect of Rituximab on the cognitive impairment in patients with secondary progressive MS (SPMS).
Methods: The present interventional study used a convenience sampling method to select the study participants from SPMS patients. All these patients had progressive disability over the last two years before being admitted in the study. Prior to the administration of Rituximab, the minimal assessment of cognitive function in the multiple sclerosis (MACFIMS) test was performed for each patient who was a candidate to be included in this study. This test was repeated by passing 6 and 12 months from the initial treatment with Rituximab. Since the data needed for this study were obtained at different time intervals, so a linear mixed model was used for their analysis. Analysis of variance (ANOVA) was also used to investigate whether time and sex generally affect the cognitive impairments in SPMS patients. A p-value <0.05 was considered as statistically significant in this study.
Results: Of the total 35 patients, 34% and 66% were men and women with a mean age of 41.33 and 41.39 years old, respectively. Rituximab showed a significant positive effect on a number of subgroups of MACFIMS test, including Controlled Oral Word Association Test (COWAT) (P-value: 0.038) and Brief Visuospatial Memory Test (BVMT-total) (P- value: 0.019).
Conclusion: The present study revealed that Rituximab has a positive effect on the cognitive impairment resulted from MS in secondary progressive patients. |
| first_indexed | 2024-04-12T09:07:04Z |
| format | Article |
| id | doaj.art-4e09f82aaedc48d79e1a8e5a92458477 |
| institution | Directory Open Access Journal |
| issn | 2008-6164 2008-6172 |
| language | English |
| last_indexed | 2024-04-12T09:07:04Z |
| publishDate | 2022-06-01 |
| publisher | Babol University of Medical Sciences |
| record_format | Article |
| series | Caspian Journal of Internal Medicine |
| spelling | doaj.art-4e09f82aaedc48d79e1a8e5a924584772022-12-22T03:39:04ZengBabol University of Medical SciencesCaspian Journal of Internal Medicine2008-61642008-61722022-06-01133484489Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosisSaeideh Salehizadeh0Roghayeh Saeidi1Mohammad Ali Sahraian2Hossein Rezaei Aliabadi3Seyedeh Nafiseh Hashemi4Sharareh Sharareh5Mohammad Reza Gheini6Shaghayegh Shahmirzaei7Mahsa Owji8Abdorreza Naser Moghadasi9 Multiple Sclerosis Research Center; Neuroscience institute; Tehran University of Medical Sciences; Tehran; Iran Multiple Sclerosis Research Center; Neuroscience institute; Tehran University of Medical Sciences; Tehran; Iran Multiple Sclerosis Research Center; Neuroscience institute; Tehran University of Medical Sciences; Tehran; Iran Bam University of Medical Sciences, Bam, Iran Statistics Department, Science Faculty, Shiraz University, Shiraz, Iran. Multiple Sclerosis Research Center; Neuroscience institute; Tehran University of Medical Sciences; Tehran; Iran Department of Neurology, Sina Hospital, Tehran University of Medical Sciences; Tehran; Iran Department of Neurology, Sina Hospital, Tehran University of Medical Sciences; Tehran; Iran Department of Neurology, Sina Hospital, Tehran University of Medical Sciences; Tehran; Iran Department of Neurology, Sina Hospital, Tehran University of Medical Sciences; Tehran; Iran Background: The present study aimed to address the effect of Rituximab on the cognitive impairment in patients with secondary progressive MS (SPMS). Methods: The present interventional study used a convenience sampling method to select the study participants from SPMS patients. All these patients had progressive disability over the last two years before being admitted in the study. Prior to the administration of Rituximab, the minimal assessment of cognitive function in the multiple sclerosis (MACFIMS) test was performed for each patient who was a candidate to be included in this study. This test was repeated by passing 6 and 12 months from the initial treatment with Rituximab. Since the data needed for this study were obtained at different time intervals, so a linear mixed model was used for their analysis. Analysis of variance (ANOVA) was also used to investigate whether time and sex generally affect the cognitive impairments in SPMS patients. A p-value <0.05 was considered as statistically significant in this study. Results: Of the total 35 patients, 34% and 66% were men and women with a mean age of 41.33 and 41.39 years old, respectively. Rituximab showed a significant positive effect on a number of subgroups of MACFIMS test, including Controlled Oral Word Association Test (COWAT) (P-value: 0.038) and Brief Visuospatial Memory Test (BVMT-total) (P- value: 0.019). Conclusion: The present study revealed that Rituximab has a positive effect on the cognitive impairment resulted from MS in secondary progressive patients.http://caspjim.com/article-1-2788-en.htmlsecondary progressive multiple sclerosis (spms)rituximabmacfimscognitive impairment |
| spellingShingle | Saeideh Salehizadeh Roghayeh Saeidi Mohammad Ali Sahraian Hossein Rezaei Aliabadi Seyedeh Nafiseh Hashemi Sharareh Sharareh Mohammad Reza Gheini Shaghayegh Shahmirzaei Mahsa Owji Abdorreza Naser Moghadasi Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis Caspian Journal of Internal Medicine secondary progressive multiple sclerosis (spms) rituximab macfims cognitive impairment |
| title | Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis |
| title_full | Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis |
| title_fullStr | Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis |
| title_full_unstemmed | Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis |
| title_short | Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis |
| title_sort | effect of rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis |
| topic | secondary progressive multiple sclerosis (spms) rituximab macfims cognitive impairment |
| url | http://caspjim.com/article-1-2788-en.html |
| work_keys_str_mv | AT saeidehsalehizadeh effectofrituximabonthecognitiveimpairmentinpatientswithsecondaryprogressivemultiplesclerosis AT roghayehsaeidi effectofrituximabonthecognitiveimpairmentinpatientswithsecondaryprogressivemultiplesclerosis AT mohammadalisahraian effectofrituximabonthecognitiveimpairmentinpatientswithsecondaryprogressivemultiplesclerosis AT hosseinrezaeialiabadi effectofrituximabonthecognitiveimpairmentinpatientswithsecondaryprogressivemultiplesclerosis AT seyedehnafisehhashemi effectofrituximabonthecognitiveimpairmentinpatientswithsecondaryprogressivemultiplesclerosis AT shararehsharareh effectofrituximabonthecognitiveimpairmentinpatientswithsecondaryprogressivemultiplesclerosis AT mohammadrezagheini effectofrituximabonthecognitiveimpairmentinpatientswithsecondaryprogressivemultiplesclerosis AT shaghayeghshahmirzaei effectofrituximabonthecognitiveimpairmentinpatientswithsecondaryprogressivemultiplesclerosis AT mahsaowji effectofrituximabonthecognitiveimpairmentinpatientswithsecondaryprogressivemultiplesclerosis AT abdorrezanasermoghadasi effectofrituximabonthecognitiveimpairmentinpatientswithsecondaryprogressivemultiplesclerosis |